US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
pharma · infections · Not applicable (submitted trial is a BE study in healthy participants)
Zaklady FarmaFarmaceutyczne Polpharma
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
Zaklady FarmaFarmaceutyczne Polpharma drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 6
- Drugs
- 15
- Patents
- 0
Zaklady FarmaFarmaceutyczne Polpharma pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Zaklady FarmaFarmaceutyczne Polpharma drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane disrupting agent
-
colistimethate sodium
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Cell membrane.
- Target
- Cell membrane
- Mechanism
- Cell membrane inhibitor
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
empagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.
-
Development asset linked to Zaklady FarmaFarmaceutyczne Polpharma in public FDA and regional records.